Experimental Neurology, Journal Year: 2024, Volume and Issue: 385, P. 115134 - 115134
Published: Dec. 29, 2024
Language: Английский
Philosophical Transactions of the Royal Society B Biological Sciences, Journal Year: 2024, Volume and Issue: 379(1899)
Published: Feb. 19, 2024
Over the past two decades, increased research has highlighted connection between endosomal trafficking defects and neurodegeneration. The endo-lysosomal network is an important, complex cellular system specialized in transport of proteins, lipids, other metabolites, essential for cell homeostasis. Disruption this pathway linked to a wide range neurodegenerative diseases, including Alzheimer's disease, Parkinson's amyotrophic lateral sclerosis, Huntington's disease frontotemporal dementia. Furthermore, there strong evidence that create opportunities diagnostic therapeutic intervention. In
Language: Английский
Citations
10
Drug Discovery Today, Journal Year: 2025, Volume and Issue: unknown, P. 104289 - 104289
Published: Jan. 1, 2025
Increasing evidence from fluid biopsies suggests activation and injury of glial cells in epilepsy. The prevalence clinical subclinical seizures neurodegenerative conditions such as Alzheimer's disease, frontotemporal dementia, others merits review comparison the effects on markers epilepsy diseases with concomitant seizures. Herein, we revisit preclinical reports alterations proteins cerebrospinal blood associated various types We consider shared distinct characteristics changes different age groups sexes, humans animal models epilepsy, compare them those reported biofluids diseases. Our analysis indicates a significant overlap response these prevalent neurological conditions.
Language: Английский
Citations
1
Genes, Journal Year: 2025, Volume and Issue: 16(2), P. 135 - 135
Published: Jan. 24, 2025
Neurodegenerative diseases, such as Alzheimer’s disease (AD), Parkinson’s (PD), Huntington’s (HD), and amyotrophic lateral sclerosis (ALS), represent a growing societal challenge due to their irreversible progression significant impact on patients, caregivers, healthcare systems. Despite advances in clinical imaging-based diagnostics, these diseases are often detected at advanced stages, limiting the effectiveness of therapeutic interventions. Recent breakthroughs genomic transcriptomic technologies, including whole-genome sequencing, single-cell RNA sequencing (scRNA-seq), CRISPR-based screens, have revolutionized field, offering new avenues for early diagnosis personalized prognosis. Genomic approaches elucidated disease-specific genetic risk factors molecular pathways, while studies identified stage-specific biomarkers that correlate with severity. Furthermore, genome-wide association (GWAS), polygenic scores (PRS), spatial transcriptomics enabling stratification patients based profiles prognostic trajectories. Advances functional genomics uncovered actionable targets, ATXN2 ALS TREM2 AD, paving way tailored strategies. achievements, challenges remain translating discoveries into practice heterogeneity complexity neurodegenerative pathophysiology. Future integration technologies holds promise transforming diagnostic paradigms, hope improved patient outcomes precision medicine approaches.
Language: Английский
Citations
1
Biosensors, Journal Year: 2025, Volume and Issue: 15(2), P. 102 - 102
Published: Feb. 11, 2025
Monitoring and assessing the progression of symptoms in neurodegenerative diseases, including Alzheimer's Parkinson's disease, are critical for improving patient outcomes. Traditional biomarkers, such as cerebrospinal fluid analysis brain imaging, widely used to investigate underlying mechanisms disease enable early diagnosis. In contrast, digital biomarkers derived from phenotypic changes-such EEG, eye movement, gait, speech analysis-offer a noninvasive accessible alternative. Leveraging portable available devices, smartphones wearable sensors, emerging promising tool ND diagnosis monitoring. This review highlights comprehensive developments emphasizing their unique advantages integration potential alongside traditional biomarkers.
Language: Английский
Citations
1
Neurobiology of Disease, Journal Year: 2024, Volume and Issue: 201, P. 106663 - 106663
Published: Sept. 7, 2024
Language: Английский
Citations
6
Molecular Biology Reports, Journal Year: 2024, Volume and Issue: 51(1)
Published: Feb. 1, 2024
Language: Английский
Citations
5
Acta Neurologica Belgica, Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 8, 2025
Language: Английский
Citations
0
bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown
Published: Jan. 17, 2025
Abstract Detection of alpha-synuclein seeding activity in tear fluid (TF) might provide a promising non-invasive biomarker for Parkinson’s disease (PD) diagnosis. In this study, we applied the amplification assay (aSynSAA) to detect misfolded (aSyn) aggregation TF from PD patients. The discovery cohort included 11 patients and 13 controls, validation consisted 9 controls without synucleinopathies. aSynSAA yielded positive results over 55% These findings were confirmed second cohort, including with prion diseases as negative control synuclein pathology. Our demonstrate first time ability distinguish between groups TF, showing highest compared groups. Further comparisons cerebrospinal (CSF) samples same individuals revealed consistent across both biofluids. highlight potential novel, accessible medium detecting Lewy body-specific PD, which could aid early diagnosis progression monitoring.
Language: Английский
Citations
0
TrAC Trends in Analytical Chemistry, Journal Year: 2025, Volume and Issue: 185, P. 118173 - 118173
Published: Feb. 3, 2025
Language: Английский
Citations
0
International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(9), P. 4271 - 4271
Published: April 30, 2025
The brain-derived neurotrophic factor (BDNF) has become one of the cornerstones neuropathology, influencing synaptic plasticity, cognitive resilience, and neuronal survival. Apart from its molecular biology, BDNF is a powerful target for transformative benefit in precision medicine, leading to innovative therapeutic approaches neurodegenerative psychiatric diseases like Alzheimer’s disease (AD), Parkinson’s (PD), major depressive disorder (MDD), post-traumatic stress (PTSD). Nevertheless, clinical applicability obstructed by hurdles delivery, patient-specific diversity, pleiotropic signaling. Here, we summarize findings research, including regulatory pathways diagnostic/prognostic biomarkers integrative approaches. We describe delivery systems, such as lipid nanoparticle-based mRNA therapies CRISPR-dCas9-based epigenetic editing that bypass obstacles BBB (blood–brain barrier) enzymatic degradation. recent implementation multiplex panels combining biodynamic indicators with tau amyloid-β signaling markers showcases novel levels specificity both early detection potential monitoring. Humanized preclinical models iPSC-derived neurons organoids point key role neurodeveloping processes, paralleling advances bridging observation environments. Moreover, tools delivering TrkB activators or AI-based dynamic care platforms enable tailored scalable treatments. This review also aims extend framework used understanding BDNF’s relevance traditional situating more work detailing actions ischemic tissues gut–brain axis context systemic health. Finally, outline roadmap incorporation BDNF-centered into worldwide healthcare, highlighting ethical issues, equity, interdisciplinary decomposition. heralds new era neuroscience revolutionizing brain health paving way advancement medicine.
Language: Английский
Citations
0